Back
Corporate News
ChrysCapital secures 70.68% stake in Novartis India, rebranding the pharmaceutical firm
30-Jul-2026, 09:14
Novartis India Limited (NIL), a BSE-listed Indian pharmaceutical company, announced that ChrysCapital has acquired a controlling 70.68% stake in the organization, marking its first majority-controlled investment in the Indian pharmaceutical sector. The transaction will see NIL adopt a new name and corporate identity, and Dr. Vikas Gupta has been appointed as Managing Director and Chief Executive Officer, with Ramesh Ramadurai assuming the role of Chairperson of the NIL board.
Novartis India Limited (NIL), a BSE-listed Indian pharmaceutical company, announced that ChrysCapital has acquired a controlling 70.68% stake in the organization, marking its first majority-controlled investment in the Indian pharmaceutical sector. The transaction will see NIL adopt a new name and corporate identity, and Dr. Vikas Gupta has been appointed as Managing Director and Chief Executive Officer, with Ramesh Ramadurai assuming the role of Chairperson of the NIL board.